CTIC Stock UPDATES Cell Therapeutics (CTIC) 2.50 09/15/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.50 $CTIC

Traders Get Bullish on Shares of Cell Therapeutics, Shares Up 7.7% (CTIC)
Comtex SmarTrend(R) - Tue Sep 09, 10:08AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 7.7% to $2.67 on 1.5x average daily volume. Cell Therapeutics has traded 1.3 million shares thus far today, vs. average volume of 866,000 shares per day. The stock has outperformed the Dow (7.7% to the Dow's -0.4%) and outperformed the S&P 500 (7.7% to the S&P's -0.4%) during today's trading.

Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:

Insider Trading Alert - MTDR, ABCO And CTIC Traded By Insiders
at The Street - Mon Aug 18, 9:15AM CDT
Stocks with insider trader activity include MTDR, ABCO and CTIC

Insider Trading Alert - CMS, CTIC And WFT Traded By Insiders
at The Street - Thu Aug 07, 9:15AM CDT
Stocks with insider trader activity include CMS, CTIC and WFT

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
PR Newswire - Thu Aug 07, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.

Upgrade Alert for Cell Therapeutics (CTIC)
Comtex SmarTrend(R) - Tue Aug 05, 6:55AM CDT
Cell Therapeutics (NASDAQ:CTIC) was upgraded from Hold to Buy at WallachBeth today. The stock closed yesterday at $2.51 on volume of 1.2 million shares, below average daily volume of 1.4 million. Cell Therapeutics, Inc. is a biopharmaceutical company. The Company researches and develops cancer drugs.

CTI BioPharma Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 04, 3:01PM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the second quarter and six months ended June 30, 2014.

The Federal Reserve Playing Analyst Damaging to Biotechnology Companies
ACCESSWIRE - Wed Jul 30, 9:06AM CDT
WHITEFISH, MT / July 30, 2014 / The July 15 U.S. Federal Reserve report on monetary policy touched off a barrage of barely polite and not very muted commentary from one end of the web to the other this past week with 32 simple words: "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The release of the report to Congress coincided with the start of Federal Reserve Chairwoman Janet Yellen's testimony before a Congressional committee. NBI, the Nasdaq Biotechnology Index, slumped from around 2,700 on Tuesday to a low of 2,536 on Thursday, a 6% nosedive, before paring the losses with an up day on Friday. Of the 120 companies in the NBI, 101 closed in the red last week, including Ligand Pharma (NASDAQ: LGND) shedding 19.4% and Raptor Pharma (NASDAQ: RPTP) falling 18.7%.

CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014
PR Newswire - Mon Jul 28, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its second quarter 2014 financial results on Monday, August 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Cell Therapeutics Up 5.4%, Shares Break Through Resistance (CTIC)
Comtex SmarTrend(R) - Mon Jul 21, 10:38AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 5.4% to $2.73 on 1.0x average daily volume. Cell Therapeutics has traded 1.7 million shares thus far today, vs. average volume of 1.7 million shares per day. The stock has outperformed the Dow (5.4% to the Dow's -0.5%) and outperformed the S&P 500 (5.4% to the S&P's -0.4%) during today's trading.

CTI BioPharma wins PIXUVRI 's marketing approval in Israel plus add-on reimbursement status in the Netherlands
M2 - Mon Jul 21, 7:19AM CDT
Biopharmaceutical company CTI BioPharma (NASDAQ:CTIC)(MTA:CTIC) on Monday announced marketing approval from the Israeli Ministry of Health (MOH) for PIXUVRI (pixantrone) for the treatment of aggressive B-cell NHL.

CTI BioPharma Expands Access To PIXUVRI® With Approval In Israel And Add-on Reimbursement Status In The Netherlands
PR Newswire - Mon Jul 21, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI® (pixantrone).

Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer

Insider Trading Alert - AAWW, CTIC And HBI Traded By Insiders
at The Street - Thu Jul 10, 9:12AM CDT
Stocks with insider trader activity include AAWW, CTIC and HBI

Acquisitions, Study Results, Merger Agreements, and Completed Trial Recruitments - Analyst Notes on Cooper, Agenus, Transcept, CTI and ANI
PR Newswire - Fri Jul 04, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.

Tuesday’s Top Biotech Stories: CTI BioPharma, Agenus, and Salix Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 01, 8:19AM CDT
Let's take a look at three stocks -- CTI BioPharma , Agenus , and Salix Pharmaceuticals -- which are all climbing higher in pre-market trading this Tuesday morning. CTI BioPharma climbs after completing enrollment in a late-stage trial ...

CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis
PR Newswire - Tue Jul 01, 12:30AM CDT
CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a $20 million development milestone payment in connection with the first treatment dosing of the last patient enrolled in PERSIST-1. CTI expects to achieve this milestone and receive payment by mid-third quarter 2014.

Insider Trading Alert - FII, RP And CTIC Traded By Insiders
at The Street - Mon Jun 30, 9:30AM CDT
Stocks with insider trader activity include FII, RP and CTIC




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 80

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 189

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 16

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 44

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 17

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Expanding Scope of Implantable Medical Devices

Updated Category News Views 122

Overview of the Implantable Medical Devices Market The global market for implantable medical devices is witnessing remarkable growth, with projections estimating it to reach approximately USD 176.33 billion by 2034, escalating at a compound annual growth rate (CAGR) of 6.14%. This rise is largely influenced by a steadily increasing prevalence of chronic diseases and an...

Continue Reading
Revolutionizing Home Financing: The Launch of Rate Intelligence

Updated Category News Views 109

Rate's Innovative AI Solution for Mortgage Lending Rate, a pioneer in financial technology, has recently introduced Rate Intelligence—an advanced AI platform that seeks to redefine the mortgage experience for both homebuyers and loan officers. By leveraging cutting-edge technology, Rate is on a mission to enhance efficiency, speed, and accuracy in the home financing...

Continue Reading
Lindahl Reed Secures OASIS+ Contracts to Enhance Services

Updated Category News Views 163

Lindahl Reed Achieves Significant OASIS+ Contract Awards Lindahl Reed, Inc., a prominent player in the technical and scientific services arena, has recently been awarded the One Acquisition Solution for Integrated Services Plus (OASIS+) – 8(a) and Women-Owned Small Business (WOSB) Multi-Agency Contract master contracts. This new development is noteworthy as it allows...

Continue Reading
Safe Bulkers (NYSE: SB) Sees 52-Week Low Amid Market Struggles

Updated Category News Views 334

Safe Bulkers (NYSE: SB) Faces Market Challenges In a challenging environment for investors, Safe Bulkers Inc. (NYSE: SB) has witnessed its stock drop to a 52-week low, currently standing at $3.4. This decline highlights the broader issues prevalent in the shipping sector, where shifts in demand and fluctuating shipping rates have placed pressure on many companies,...

Continue Reading
Emerging Cybersecurity Trends for 2026: AI's Dual Role

Updated Category News Views 280

Understanding 2026: Cybersecurity Predictions and Insights In an era where technology is evolving at a rapid pace, organizations find themselves at a critical juncture. The proliferation of AI poses both unprecedented opportunities and significant threats. Businesses must stay vigilant against a historic wave of DNS exploitation alongside an evolving threat landscape. As...

Continue Reading